Every material Form 8-K Immuneering Corp has filed with the SEC since June 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Immuneering reported a third-quarter 2026 net loss of $24.2 million, or $0.37 per share, up from $15.0 million in the same quarter of 2025, as research and development spending rose to $20.7 million. The company said its cash runway now extends into the fourth quarter of 2028, but cash, cash equivalents and marketable securities fell to $166.1 million from $217.0 million at December 31, 2025, and the filing reports no revenue.
Q3 2026 net loss was $24.2 million ($0.37 per share), versus $15.0 million ($0.38 per share) in Q3 2025.
R&D expenses were $20.7 million in Q3 2026, compared with $10.9 million a year earlier, citing higher clinical costs and personnel.
Cash, cash equivalents and marketable securities were $166.1 million at September 30, 2026, down from $217.0 million at December 31, 2025.
Phase 3 MAPKeeper 301 enrollment target expanded from 510 to 570 patients; the mid-2028 topline readout may be accelerated.
Immuneering reported a second-quarter 2026 net loss of $17.3 million, or $0.27 per share, up from $14.4 million, or $0.40 per share, a year earlier. Cash, cash equivalents and marketable securities fell to $182.7 million at June 30, 2026 from $217.0 million at December 31, 2025, and the company says that cash is expected to fund operations into 2029.
Net loss was $17.3 million ($0.27 per share) for Q2 2026, compared with $14.4 million ($0.40 per share) for Q2 2025.
R&D expenses rose to $14.0 million from $10.5 million, mainly due to increased clinical costs for the atebimetinib program.
Cash and marketable securities were $182.7 million at June 30, 2026, versus $217.0 million at December 31, 2025.
Topline data from the Phase 3 MAPKeeper 301 trial is expected in mid-2028.
Immuneering appointed Andrew Gengos as Chief Financial Officer and Treasurer, effective when he starts employment, which is expected on or before July 16, 2026. He succeeds Mallory Morales as principal financial officer, while she remains Senior Vice President Finance and Chief Accounting Officer. The filing describes a $530,000 base salary and a 650,000-share option grant as inducements, which matters to shareholders because it sets the compensation terms for the company's top finance role.
Andrew Gengos was appointed CFO and Treasurer by the Board on June 11, 2026, with employment expected to begin on or before July 16, 2026.
Gengos previously served as CFO of Terns Pharmaceuticals from February 2025 to May 2026.
Compensation includes a $530,000 annual base salary, a target bonus of 40% of base salary, and an option to purchase 650,000 shares.
Mallory Morales will stop serving as principal financial officer but remains Chief Accounting Officer.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Immuneering Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →